This article is more than 5 years old. Information may no longer be current.

Ozurdex for retinal vein occlusion available in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press release.

Ozurdex (dexamethasone intravitreal implant 0.7 mg) was approved in October 2017 and is the first intravitreal injection approved for RVO in China.

“RVO is a devastating condition that affects millions of patients in China. ... Being able to offer these patients a proven treatment option allows ophthalmologists to consider a more tailored management approach, helping to reduce the treatment burden for patients and alleviate pressure on local eye care services,” Dai Hong, director of ophthalmology at Beijing Hospital, said in the release.